deltatrials
Terminated PHASE4 INTERVENTIONAL 4-arm NCT00449618

Comparison of Awakening Versus Bedtime Dosing of Aspirin in Pre-Hypertension or Mild Essential Hypertension

A Prospective, Randomized, Multi-Center, Double-Blind Crossover Study to Compare Awakening Versus Bedtime Administration of 100 mg Aspirin or Placebo in Subjects With High-Normal Blood Pressure or Mild Essential Hypertension

Sponsor: Bayer

Conditions High-Normal Blood Pressure Mild Essential Hypertension
Interventions Ambulatory blood pressure monitoring Aspirin 100 mg Chronotherapy, timing of medication Placebo
Updated 5 times since 2017 Last updated: Dec 31, 2008 Started: Jan 31, 2007 Primary completion: Dec 31, 2008 Completion: Dec 31, 2008
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Not enough recruitment during the proposed period.

Other terminated trials from Bayer

See all terminations from Bayer

Listed as NCT00449618, this PHASE4 trial focuses on High-Normal Blood Pressure and Mild Essential Hypertension and remains terminated or withdrawn. Sponsored by Bayer, it has been updated 5 times since 2007, reflecting limited change activity. This study contributes longitudinal data to the cardiovascular research landscape.

Status Flow

~Jan 2017 – ~Jun 2018 · 17 months · monthly snapshotTerminated~Jun 2018 – ~Jan 2021 · 31 months · monthly snapshotTerminated~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshotTerminated~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotTerminated~Sep 2024 – present · 24 months · monthly snapshotTerminated

Change History

5 versions recorded

  1. Sep 2024 — Present [monthly]

    Terminated PHASE4

  2. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE4

  3. Jan 2021 — Jul 2024 [monthly]

    Terminated PHASE4

  4. Jun 2018 — Jan 2021 [monthly]

    Terminated PHASE4

  5. Jan 2017 — Jun 2018 [monthly]

    Terminated PHASE4

    First recorded

Jan 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Bayer
  • Hospital Clinico Universitario de Santiago
  • University of Vigo
Data source: University of Vigo

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations